Recently, according to foreign media reports, Endogenex completed a $50 million (approximately 350 million yuan) Series C extension financing. This funding will be used to complete the development of its type 2 diabetes electrical pulse therapy and submit the technology to the U.S. Food and Drug Administration (FDA) for approval.
Endogenex was founded in 2017 and focuses on the diabetes field. Its promising product—the ReCET system—targets the upper small intestine, specifically the duodenal region, aiming to reset inflammation and dysfunctional tissues associated with type 2 diabetes and improve the intestine's ability to regulate blood sugar, appetite, and digestion.
According to Endogenex, the ReCET system can deliver pulsed electric fields to the inner mucosal layer of the organ through an endoscopic electrode array, thereby clearing dysfunctional cells and stimulating tissue regeneration while avoiding potential thermal damage. This technology has previously received FDA breakthrough device designation.
It is reported that shortly before this financing round, Endogenex announced preliminary clinical research results for the ReCET system. Its proof-of-concept project conducted in the United States and Australia released 48-week outcome data. Over 70 participants with poorly controlled type 2 diabetes received this therapy, achieving a 100% technical success rate. Among them, a group of 31 patients received dual treatment with the second-generation high-energy device. Within 48 weeks, the average HbA1c level decreased by 1.5 percentage points, and body weight was reduced by an average of approximately 5.4 kg, equivalent to 5% to 6% of body weight.
Simultaneously, blood glucose monitoring data showed that the proportion of time patients spent within the healthy blood glucose range increased from 55.8% to 82.1%. The trial results were published in the journal Diabetes, Obesity and Metabolism. Overall, the data indicate that its pulsed electric field system met safety targets and achieved metabolic improvements in glycated hemoglobin (HbA1c), fasting blood glucose levels, and body weight.
It is worth noting that Endogenex has completed multiple rounds of financing previously. This current round is a Series C extension. The Series C financing was completed on June 25, 2024, with $88 million raised at that time, intended for completing key ReCET clinical studies.
This 50millioninjectionwillbeusedtofundpivotalclinicalstudiesandtheFDAapprovalprocess.Thetotalfinancingfromthesetworoundshasreached138 million.
Regarding this financing, Endogenex CEO Stacey Pugh stated: "Type 2 diabetes continues to place a heavy burden on patients, healthcare providers, and the healthcare system. Even with the best available therapies, including GLP-1 receptor agonists and SGLT2 inhibitors, the disease often continues to progress. We believe this is because an important part of the disease—the gut—has remained untreated. By restoring the health of the duodenum, our goal is to help patients not just manage symptoms but potentially alter the course of their disease. This funding brings us a significant step closer to that goal."

https://news.yaozh.com/archive/47631.html